Axsome Therapeutics, Inc a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved AUVELITYTM (dextromethorphan HBr -bupropion HCl) extended-release tablets for the treatment of major depressive disorder (MDD) in adults.
- Read more about Axsome Therapeutics announces FDA Approval of AUVELITY
- Log in or register to post comments
source https://www.pharmatutor.org/pharma-news/2022/axsome-therapeutics-announces-fda-approval-of-auvelity
No comments:
Post a Comment